Zobrazeno 1 - 10
of 350
pro vyhledávání: '"W J, Sandborn"'
Autor:
V Jairath, G Zou, G Radulescu, J Sigler, S C Mcfarlane, S Adsul, M Freire, L Peyrin-Biroulet, J F Colombel, G W Moran, S Sebastian, S Travis, S Vermeire, W J Sandborn, G R D’Haens, B G Feagan
Publikováno v:
Journal of Crohn's and Colitis. 17:i826-i829
Background Symptoms, endoscopy, histology, and biomarkers are used to evaluate disease activity and response to therapy in ulcerative colitis (UC). Histologic disease activity may persist in ~25% of patients with normal-appearing endoscopic mucosa, a
Autor:
D Bettenworth, M E Baker, W Bemelmann, D Bruining, G D’Haens, A D’Hoore, A Dignass, I Dotan, B G Feagan, R Feakins, P Fleshner, J G Fletcher, I Gordon, C Ha, H Gaylyn, V Jairath, C Lu, R Lyu, S C Ng, J Panes, G Rogler, R Mao, J Rimola, W J Sandborn, B Siegmund, M S Silverberg, S Taylor, B Verstockt, F Rieder
Publikováno v:
Journal of Crohn's and Colitis. 17:i418-i420
Background Small bowel fibrostenotic strictures are common in patients with Crohn’s disease (CD). No global consensus recommendations on definitions, diagnosis and clinical management are available. Methods Several systematic reviews followed by a
Autor:
V Jairath, G Zou, Z Wang, S Adsul, J F Colombel, G R D’Haens, M Freire, G W Moran, L Peyrin-Biroulet, W J Sandborn, S Sebastian, S Travis, S Vermeire, G Radulescu, J Sigler, S Mcfarlane, N Arya, M Beaton, P Bossuyt, D Green, W Harlan III, M Horynski, M Klopocka, R Petroniene, M S Silverberg, L Wolanski, B G Feagan
Publikováno v:
Journal of Crohn's and Colitis. 17:i716-i717
Background The optimal treatment target for ulcerative colitis (UC) is uncertain. The VERDICT trial in moderate to severe UC aims to determine if a treatment target of corticosteroid (CS)-free symptomatic + endoscopic + histologic remission is superi
Publikováno v:
Journal of Crohn's and Colitis. 17:i878-i879
Background VTX002 is an oral selective sphingosine 1-phosphate-1 receptor (S1P1R) modulator in clinical development for treatment of ulcerative colitis (UC). Single and multiple doses of a spray-dried dispersion (SDD) oral suspension of VTX002 were w
Autor:
Ramesh P. Arasaradnam, David Rowbotham, Rupert W. Leong, Maria T. Abreu, L Peyrin-Biroulet, W J Sandborn, Ilia Tikhonov, Bruce E. Sands, Y Miao, Ellen Scherl, Hongyan Zhang, Waqqas Afif, Silvio Danese, Colleen Marano, Remo Panaccione, Tadakazu Hisamatsu
Publikováno v:
Journal of Crohn's and Colitis. 15:S113-S115
Background Ustekinumab (UST) is an IL-12/23p40 antagonist used to treat pts with moderate-to-severe ulcerative colitis (UC). The ongoing UNIFI long-term extension (LTE) evaluates subcutaneous (SC) 90mg UST maintenance therapy, with efficacy (wk152) a
Autor:
B G Feagan, E V Loftus, S Danese, S Vermeire, W J Sandborn, T Ritter, R Mehta, U Seidler, F Seibold, I Beales, H Kim, J McNally, C Yun, S Zhao, X Liu, C Tasset, R Besuyen, M Watanabe, S Schreiber, G Rogler, T Hibi, L Peyrin-Biroulet
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 4:18-20
Aims The SELECTION (NCT02914522) Induction Studies evaluated the efficacy/safety of filgotinib (FIL), a preferential JAK1 inhibitor, as induction therapy for patients (pts) with moderately to severely active ulcerative colitis (UC) who were biologic-
Autor:
G Akhundova-Unadkat, L Peyrin-Biroulet, Severine Vermeire, Bruce E. Sands, Michael Chiorean, CJ Rabbat, J Panés, S W Schreiber, Snehal Naik, W J Sandborn
Publikováno v:
Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV).
Autor:
W J Sandborn, I Jovanovic, AnnKatrin Petersen, Stephen B. Hanauer, Brian G. Feagan, Britta Siegmund, D.K. Chitkara, Subrata Ghosh, G R D’Haens, S Danese, Lorna Charles, D Wolf
Publikováno v:
Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV).
Autor:
R Koch, S Zhao, R. Besuyen, Edward V. Loftus, Severine Vermeire, Timothy E Ritter, J McNally, X Liu, Toshifumi Hibi, C Yun, Chantal Tasset, Frank Seibold, Laurent Peyrin-Biroulet, Mamoru Watanabe, R Mehta, W J Sandborn, Ian L P Beales, Silvio Danese, Ursula Seidler, BC Feagan, Stefan Schreiber, Gerhard Rogler, Hyo-Jong Kim
Publikováno v:
Zeitschrift für Gastroenterologie.
Autor:
Rajiv Mundayat, Daniel Quirk, W J Sandborn, Xiang Guo, Irene Modesto, Chinyu Su, Javier P. Gisbert, Walter Reinisch, Michael Chiorean
Publikováno v:
Journal of Crohn's and Colitis. 14:S416-S418
Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib in patients with UC were evaluated in two Phase 3 induction studies (OCTAVE Induction 1 and 2; NCT0146576